How The MDR Is Making The EU Competitively Backward
Executive Summary
Pedantic versus pragmatic implementation of the EU MDR and its guidances, as well as notified bodies struggling with capacity and new processes, are creating a clunky, slow and expensive EU regulatory system that could damage EU industry, delegates heard at the RAPS Convergence meeting earlier this week.
You may also be interested in...
European Parliament Gives Final Go Ahead To EMA’s New Roles In Devices Oversight
The new EU regulation on increasing powers of the European Medicines Agency in future health crises applies as of 1 March; it controversially sees the agency become more involved in device oversight.
Commission Publishes Draft Implementing Regulation For Insufficiently Regulated Products
At last, common specifications for different groups of products that do not have an intended medical purpose but are covered in the scope of the EU’s Medical Device Regulation, are on the way.
MHRA's Graeme Tunbridge Joins BSI Notified Body
Graeme Tunbridge is looking forward to a new career with notified body, BSI, after nearly two decades as a civil servant. But where does his departure leave the UK MHRA at a time of critical change?